Celcuity Q1 2023 net loss $11.9M; Phase 1b gedatolisib shows median PFS 48.6 months

Celcuity Inc.

2024-Q1 EPS reported -$0.55

Net loss of $11.9M ($0.55 loss per share) vs $7.9M ($0.53 loss per share) in Q1 2022.
R&D expenses $11.3M, up from $6.7M, driven by VIKTORIA-1 Phase 3 trial costs.
Cash and short-term investments $157.5M at March 31, 2023.
Phase 1b gedatolisib data: median PFS 48.6 months in treatment-naïve HR+/HER2- advanced breast cancer.
VIKTORIA-1 Phase 3 enrollment on track for primary analysis of PIK3CA WT subgroup in H2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Celcuity Inc. reported first quarter ended March 31, 2023 results: net income Net loss for the first quarter of 2023 was $11.9 million, EPS $0.55 loss per share.

Period: first quarter ended March 31, 2023
Net income: Net loss for the first quarter of 2023 was $11.9 million
EPS: $0.55 loss per share
Result: reported results

Exact text from the filing

Net loss for the first quarter of 2023 was $11.9 million, or $0.55 loss per share, compared to a net loss of $7.9 million, or $0.53 loss per share, for the first quarter of 2022.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Celcuity Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-017289

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.